High-throughput screening of tyrosine kinase inhibitor cardiotoxicity with human induced pluripotent stem cells
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
Tyrosine kinase inhibitors (TKIs), despite their efficacy as anticancer therapeutics, are associated with cardiovascular side effects ranging from induced arrhythmias to heart failure. We used human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs), generated from 11 healthy individuals and 2 patients receiving cancer treatment, to screen U.S. Food and Drug Administration-approved TKIs for cardiotoxicities by measuring alterations in cardiomyocyte viability, contractility, electrophysiology, calcium handling, and signaling. With these data, we generated a "cardiac safety index" to reflect the cardiotoxicities of existing TKIs. TKIs with low cardiac safety indices exhibit cardiotoxicity in patients. We also derived endothelial cells (hiPSC-ECs) and cardiac fibroblasts (hiPSC-CFs) to examine cell type-specific cardiotoxicities. Using high-throughput screening, we determined that vascular endothelial growth factor receptor 2 (VEGFR2)/platelet-derived growth factor receptor (PDGFR)-inhibiting TKIs caused cardiotoxicity in hiPSC-CMs, hiPSC-ECs, and hiPSC-CFs. With phosphoprotein analysis, we determined that VEGFR2/PDGFR-inhibiting TKIs led to a compensatory increase in cardioprotective insulin and insulin-like growth factor (IGF) signaling in hiPSC-CMs. Up-regulating cardioprotective signaling with exogenous insulin or IGF1 improved hiPSC-CM viability during cotreatment with cardiotoxic VEGFR2/PDGFR-inhibiting TKIs. Thus, hiPSC-CMs can be used to screen for cardiovascular toxicities associated with anticancer TKIs, and the results correlate with clinical phenotypes. This approach provides unexpected insights, as illustrated by our finding that toxicity can be alleviated via cardioprotective insulin/IGF signaling.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“they generated a “cardiac safety index” to reflect the safety of existing tyrosine kinase inhibitors [23].”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [23]
The cited source says what the claim attributes to it.
In the citing paper
“Sharma et al., 2017 performed a high-throughput toxicity screen assessing the cardiotoxicity of small molecule tyrosine kinase inhibitors.”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [23]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors
Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., & Yamanaka, S. (2007) · Cell · doi:10.1016/j.cell.2007.11.019 · Cited by 20,221
Grothey, A., Cutsem, E. V., Sobrero, A., Siena, S., Falcone, A., Ychou, M., Humblet, Y., Bouché, O., Mineur, L., Barone, C., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61900-x · Cited by 2,895
van der Graaf, W. T., Blay, J.-Y., Chawla, S. P., Kim, D.-W., Bui-Nguyen, B., Casali, P. G., Schöffski, P., Aglietta, M., Staddon, A. P., Beppu, Y., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60651-5 · Cited by 2,102
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
Talpaz, M., Shah, N. P., Kantarjian, H., Donato, N., Nicoll, J., Paquette, R., Cortes, J., O'Brien, S., Nicaise, C., Bleickardt, E., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055229 · Cited by 1,760
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
Byrd, J. C., Brown, J. R., O'Brien, S., Barrientos, J. C., Kay, N. E., Reddy, N. M., Coutre, S., Tam, C. S., Mulligan, S. P., Jaeger, U., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1400376 · Cited by 1,639
Chemically defined generation of human cardiomyocytes
Burridge, P. W., Matsa, E., Shukla, P., Lin, Z. C., Churko, J. M., Ebert, A. D., Lan, F., Diecke, S., Huber, B., Mordwinkin, N. M., et al. (2014) · Nature Methods · doi:10.1038/nmeth.2999 · Cited by 1,606 · cited 5×
“Chemically defined differentiation of hiPSC-CMs The hiPSCs were differentiated into hiPSC-CMs using a chemically defined protocol and maintained in medium supplemented with human albumin and ascorbic acid (8).”
BackgroundMethodInfluentialSelf-citationDemetri, G. D., Reichardt, P., Kang, Y.-K., Blay, J.-Y., Rutkowski, P., Gelderblom, H., Hohenberger, P., Leahy, M., von Mehren, M., Joensuu, H., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61857-1 · Cited by 1,406
Wilhelm, S. M., Dumas, J., Adnane, L., Lynch, M., Carter, C. A., Schütz, G., Thierauch, K., & Zopf, D. (2011) · International Journal of Cancer · doi:10.1002/ijc.25864 · Cited by 1,355 · cited 1×
“This is reasonable because sorafenib and regorafenib (also known as fluoro-sorafenib) have similar molecular structures (24).”
BackgroundCardiovascular Complications of Cancer Therapy
Yeh, E. T. H., & Bickford, C. L. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.02.050 · Cited by 1,275 · cited 1×
“However, some TKIs are linked to severe cardiotoxicities including heart failure, reduced left ventricular ejection fraction, myocardial infarction, or arrhythmias (2, 3).”
BackgroundPatient-Specific Induced Pluripotent Stem-Cell Models for Long-QT Syndrome
Moretti, A., Bellin, M., Welling, A., Jung, C. B., Lam, J. T., Bott-Flügel, L., Dorn, T., Goedel, A., Höhnke, C., Hofmann, F., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908679 · Cited by 1,251
Cited by
Items 201–300 of 442
Granata, A. (2023) · BMC Cardiovascular Disorders · doi:10.1186/s12872-023-03227-6 · Cited by 15
Breakthrough in large-scale production of iPSCs-derived exosomes to promote clinical applications
Chen, X., Li, K., Chen, J., & Tan, S. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1257186 · Cited by 15
“Since they were first reported in 2006, iPSCs have been seem as a promising cell source for drug screening (Rana et al., 2017; Sharma et al., 2017), organoid formation (Nguyen et al.”
BackgroundStern, S., Liang, D., Li, L., Kurian, R., Lynch, C., Sakamuru, S., Heyward, S. A., Zhang, J., Kareem, K., Chun, Y. W., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.153868 · Cited by 15
Matsui, T., Miyamoto, K., Yamanaka, K., Okai, Y., Pfeiffer, E. R., Harada, K., Wagoner, M. P., & Shinozawa, T. (2019) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2019.114761 · Cited by 15
Pinheiro, E. A., Magdy, T., & Burridge, P. W. (2020) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-020-09962-x · Cited by 15
“Other assays for viability include water-soluble tetrazolium salt or cell counts that exclude nonviable cells [76, 81].”
MethodSelf-citationAbecasis, B., Canhão, P. G. M., de Almeida, H. V., Calmeiro, T., Fortunato, E. M. C., Gomes‐Alves, P., Serra, M., & Alves, P. M. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.580744 · Cited by 16
Lam, C. K., & Wu, J. C. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy388 · Cited by 16
Self-citationPerry, T. R., Roberts, M. L., Sunkara, B., Maddula, R., McLeish, T., Gomez, J., Lucas, J., Rayan, D., Patel, S., Liang, M., et al. (2021) · Current Oncology Reports · doi:10.1007/s11912-021-01066-2 · Cited by 16
Promising tools for future drug discovery and development in antiarrhythmic therapy
Mondéjar‐Parreño, G., Sánchez-Pérez, P., Cruz, F. M., & Jalife, J. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.124.001297 · Cited by 17
Izumi‐Nakaseko, H., Fujiyoshi, M., Hagiwara-Nagasawa, M., Goto, A., Chiba, K., Kambayashi, R., Naito, A. T., Ando, K., Kanda, Y., Ishii, I., et al. (2019) · Cardiovascular Toxicology · doi:10.1007/s12012-019-09538-5 · Cited by 14
Ziegler, R., Häusermann, F., Kirchner, S., & Polonchuk, L. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.639824 · Cited by 14
“Recent studies have demonstrated that patient-specific hiPSC-CMs can be utilized to reproduce the cardiotoxic effect of doxorubicin (61) and tyrosine kinase inhibitors in vitro (62).”
BackgroundMultiscale mapping of transcriptomic signatures for cardiotoxic drugs
Hansen, J., Xiong, Y., Siddiq, M. M., Dhanan, P., Hu, B., Shewale, B., Yadaw, A. S., Jayaraman, G., Tolentino, R. E., Chen, Y., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-52145-4 · Cited by 16
“11 and 12), our PK/PD algorithm allowed re-identi fi cationofthevariant rs2229774 (Fig.4C,SupplementaryData25) within the coding region of the RARG gene 15 , one out of three genomic variants with the strongest evidence for AIC 59 .”
InfluentialMusunuru, K., Arora, P. K., Cooke, J. P., Ferguson, J. F., Hershberger, R. E., Hickey, K. T., Lee, J., Lima, J. A. C., Loscalzo, J., Pereira, N. L., et al. (2018) · Circulation Genomic and Precision Medicine · doi:10.1161/hcg.0000000000000046 · Cited by 16
Modeling Hematological Diseases and Cancer With Patient-Specific Induced Pluripotent Stem Cells
Kim, H., & Schaniel, C. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02243 · Cited by 15
Matsumoto, R., Yamamoto, T., & Takahashi, Y. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910184 · Cited by 16
Unveiling the Cardiotoxicity Conundrum: Navigating the Seas of Tyrosine Kinase Inhibitor Therapies
Ekram, J., Rathore, A. H., Avila, C., Hussein, R., & Alomar, M. (2024) · Cancer Control · doi:10.1177/10732748241285755 · Cited by 14
Suga, T., Kitani, T., Kogure, M., Oishi, M., Ito, F., Hoshino, A., Ogata, T., Ikeda, K., & Matoba, S. (2025) · Cardiovascular Research · doi:10.1093/cvr/cvaf022 · Cited by 16
Self-citationVo, Q. D., Nakamura, K., Saito, Y., Akagi, S., Miyoshi, T., & Yuasa, S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26114984 · Cited by 13
“For instance, Sharma et al. employed high-content imaging of iPSC-CMs to screen kinase inhibitors and chemotherapeutics, revealing distinctive cardiotoxic phenotypes such as disrupted beating patterns, calcium dysregulation, and morphological abnormalities [129].”
Pang, L., Liu, Z., Feng, W., Cai, C., & Yang, X. (2020) · Archives of Toxicology · doi:10.1007/s00204-020-02952-7 · Cited by 15
Droplet Microarray Based Screening Identifies Proteins for Maintaining Pluripotency of hiPSCs
Liu, Y., Bertels, S., Reischl, M., Peravali, R., Bastmeyer, M., Popova, A. A., & Levkin, P. A. (2022) · Advanced Healthcare Materials · doi:10.1002/adhm.202200718 · Cited by 13
Liu, Q., Li, S., Qiu, Y., Zhang, J., Rios, F. J. O., Zou, Z., & Touyz, R. M. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1002438 · Cited by 14
“Various TKIs that inhibit VEGFR/PDGFR were shown to induce significant cell death in human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) (132).”
BackgroundAnthracyclines induce cardiotoxicity through a shared gene expression response signature
Matthews, E. R., Johnson, O. D., Horn, K., Gutiérrez, J. A., Powell, S. R., & Ward, M. C. (2024) · PLoS Genetics · doi:10.1371/journal.pgen.1011164 · Cited by 13
Cancer in a dish: progress using stem cells as a platform for cancer research.
Liu, M., Tu, J., Gingold, J. A., Kong, C. S. L., & Lee, D. (2018) · Europe PMC (PubMed Central) · Cited by 14
Li, C., Wu, W., Xing, J., Yan, W., Zhang, J., Sun, J., Zhang, Z., Qiu, S., Xu, Y., & Wang, X. (2023) · Food and Chemical Toxicology · doi:10.1016/j.fct.2023.113743 · Cited by 12
Rossler, K. J., de Lange, W. J., Mann, M. W., Aballo, T. J., Melby, J. A., Zhang, J., Kim, G., Bayne, E. F., Zhu, Y., Farrell, E. T., et al. (2024) · JCI Insight · doi:10.1172/jci.insight.172168 · Cited by 12
Huang, M.-F., Pang, L. K., Chen, Y., Zhao, R., & Lee, D. (2021) · Cells · doi:10.3390/cells10112823 · Cited by 13
Sun, S., Qin, J., Liao, W., Gao, X., Shang, Z., Luo, D., & Xiong, S. (2023) · Cardiovascular Toxicology · doi:10.1007/s12012-023-09800-x · Cited by 13
“These findings indicate a new role for exogenous insulin or IGF1 in TKIs-induced cardiotoxicity in dependent manner [122].”
BackgroundConcise Review: Precision Matchmaking: Induced Pluripotent Stem Cells Meet Cardio-Oncology
Nair, P., Prado, M., Perea‐Gil, I., & Karakikes, I. (2019) · Stem Cells Translational Medicine · doi:10.1002/sctm.18-0279 · Cited by 13
Predictive in vitro toxicology screening to guide chemical design in drug discovery
Johansson, J., Larsson, M. H., & Hornberg, J. J. (2019) · Current Opinion in Toxicology · doi:10.1016/j.cotox.2019.08.005 · Cited by 13
Predicting individual-specific cardiotoxicity responses induced by tyrosine kinase inhibitors
Shim, J. V., Xiong, Y., Dhanan, P., Dariolli, R., Azeloglu, E. U., Hu, B., Jayaraman, G., Schaniel, C., Birtwistle, M. R., Iyengar, R., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1158222 · Cited by 15
“These studies have shown the value of the iPSC-CMmodel for allowing both Omics assays, such as gene expression and protein expression, and physiological assays, such as action potentials (Sharma et al., 2017), contractile force (Jacob et al.”
BackgroundResultInfluentialYang, H., Qiu, S., Yao, T., Liu, G., Liu, J., Guo, L., Shi, C., Xu, Y., & Ma, J. (2024) · Toxicology Letters · doi:10.1016/j.toxlet.2024.05.005 · Cited by 13
Engineering cardiology with miniature hearts
Xia, X., Hu, M., Zhou, W., Jin, Y., & Yao, X. (2025) · Materials Today Bio · doi:10.1016/j.mtbio.2025.101505 · Cited by 15
Generation of Human iPSCs by Protein Reprogramming and Stimulation of TLR3 Signaling
Liu, C., Ameen, M., Himmati, S., Thomas, D., & Sayed, N. (2020) · Methods in molecular biology · doi:10.1007/978-1-0716-1084-8_10 · Cited by 11
Self-citationYang, Y., Yang, H., Kiskin, F. N., & Zhang, J. Z. (2024) · Medical Review · doi:10.1515/mr-2023-0059 · Cited by 12
“In one of the studies utilizing hiPSC-CMs for cardiotoxicity testing, a high-throughput toxicity screen was performed to assess the cardiotoxicity of TKIs by establishing a “ cardiac safety index ” (CSI) using cell survival and contractility parameters [124].”
MethodFourier-domain-compressed optical time-stretch quantitative phase imaging flow cytometry
Li, R., Weng, Y., Wei, S., Lin, S., Huang, J. L., Song, C., Shen, H., Hou, J., Xu, Y., Mei, L., et al. (2024) · Photonics Research · doi:10.1364/prj.523653 · Cited by 10
Cardiometabolic disease and cardio-oncology: Insights from iPSC models and tissue engineering
Kojic, A., Moslehi, J. J., Ky, B., & Wu, J. C. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102261 · Cited by 14
Self-citationHuman cardiac organoids for disease modeling and drug discovery
Escopete, S. S., Arzt, M., Mozneb, M., Moses, J., & Sharma, A. (2025) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2025.08.004 · Cited by 11
Self-citationChemically Defined Production of Tri‐Lineage Human iPSC‐Derived Cardiac Spheroids
Arzt, M., Pohlman, S., Mozneb, M., & Sharma, A. (2023) · Current Protocols · doi:10.1002/cpz1.767 · Cited by 12
“767 © 2023 Wiley Periodicals LLC. Arzt et al. 1 of 25 differentiation (Sharma et al., 2017).”
BackgroundSelf-citationYao, S., Dong, S., Ding, J., Rong, Y., Zhang, Y., Chen, H., Chen, J., Chen, Y.-X., Yan, H., Dai, Z., et al. (2019) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22793 · Cited by 17
“We evaluated the gene expression response of ANGPT1, ANGPT2, and the proportion of these two genes in patient-specific human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) during treatment with the TIE2 inhibitor, Regorafenib.59 The results showed that the expression F IGURE 4 Kaplan-Meier curves for…”
BackgroundSelf-citationMa, C., Wu, Z., Wang, X., Huang, M., Wei, X., Wang, W., Qu, H., Qiaolongbatu, X., Lou, Y., Jing, L., et al. (2022) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2022.116162 · Cited by 10
Zhao, S. R., Mondéjar‐Parreño, G., Li, D., Shen, M., & Wu, J. C. (2022) · Journal of Visualized Experiments · doi:10.3791/64265 · Cited by 12
Self-citationGintant, G. A., & Traebert, M. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2020.1736549 · Cited by 10
Development and application of 3D cardiac tissues derived from human pluripotent stem cells
Ohno, M., Tani, H., & Tohyama, S. (2025) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2024.101049 · Cited by 9
Application of human cardiac organoids in cardiovascular disease research
Zhang, H., Qu, P., Liu, J., Cheng, P., & Lei, Q. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1564889 · Cited by 10
Solomon, A. D., Dabral, S., Brajesh, R. G., Day, B. W., Juric, M., Zielonka, J., Bosnjak, Z. J., & Pant, T. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26093966 · Cited by 13
“This suggests that the heart may respond to VEGFR2/PDGFR signaling disruption by activating protective mechanisms to maintain cellular integrity [233].”
Thiab, S., Azeez, J. M., Anala, A. D., Nanda, M., Khan, S., Butler, A. E., & Nandakumar, M. (2025) · Cells · doi:10.3390/cells14151188 · Cited by 12
“IR, a significant risk factor for heart disease, can be studied using iPSC-cardiomyocytes from IR patients, which show impaired glucose uptake, mitochondrial dysfunction, and altered gene expression [157,158].”
van Hassselt, J. G. C., & Iyengar, R. (2017) · Current Opinion in Systems Biology · doi:10.1016/j.coisb.2017.05.006 · Cited by 10
Lavine, K. J., & Greenberg, M. J. (2020) · Heart Failure Reviews · doi:10.1007/s10741-020-10021-5 · Cited by 9
Use of Hipsc to Explicate Genomic Predisposition to AnthrAcycline-Induced Cardiotoxicity
Magdy, T., & Burridge, P. W. (2021) · Pharmacogenomics · doi:10.2217/pgs-2020-0104 · Cited by 10
Self-citationVelayutham, N., Garbern, J. C., Elwell, H., Zhuo, Z., Rüland, L., Alvarez, F. E., Frontini, S., Carreras, Y. R., Eichholtz, M., Ricci-Blair, E. M., et al. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.033155 · Cited by 9
Manhas, A., Liu, Y., Noishiki, C., Wu, D., Tripathi, D., Mirza, S., Thomas, D., Liu, L., Guha, A., Nguyen, P. K. P., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adv9403 · Cited by 10
Self-citationOrgans-on-chip models for cardiovascular drug development
Zimmermann, W. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab229 · Cited by 8
Li, W., Han, J., & Entcheva, E. G. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2261-2_2 · Cited by 8
Uncertainty-aware traction force microscopy
Kandasamy, A., Yeh, Y., Serrano, R., Mercola, M. A., & del Álamo, J. C. (2025) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1013079 · Cited by 12
Self-citationIntensive care for human hearts in pluripotent stem cell models
Golforoush, P. A., & Schneider, M. D. (2020) · npj Regenerative Medicine · doi:10.1038/s41536-020-0090-7 · Cited by 9
Cherian, R. M., Prajapati, C., Penttinen, K., Häkli, M., Koivisto, J. T., Pekkanen-Mattila, M., & Aalto‐Setälä, K. (2022) · Cell Biology and Toxicology · doi:10.1007/s10565-022-09742-0 · Cited by 8
“Over the past decade, many studies have shown the use of iPSC-CMs to assess the cardiac toxicity of different drugs (Narkar et al. 2022; Sharma et al. 2017; Thomas et al. 2021).”
BackgroundUsing iPSC Models to Probe Regulation of Cardiac Ion Channel Function
Bruyneel, A. A. N., McKeithan, W. L., Feyen, D. A. M., & Mercola, M. A. (2018) · Current Cardiology Reports · doi:10.1007/s11886-018-1000-0 · Cited by 8
Self-citationObal, D., & Wu, J. C. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15228 · Cited by 8
“…combined patch-clamp electrophysiological measurement and single-cell RNA sequencing [scRNA-seq; Fuzik et al., 2016], HTS [McKeithan et al., 2017; Sharma et al., 2017], Ca2+ screens [Jones & Bunnage, 2017; Stacey et al., 2018], and 3D tissue chips [Spira, Shmoel, Huang, & Erez, 2018]) may…”
Self-citationNi, X., Yang, Z., Ye, L., Han, X., Zhao, D., Ding, F., Ding, N., Wu, H., Yu, M., Xu, G., et al. (2021) · Acta Pharmacologica Sinica · doi:10.1038/s41401-021-00621-8 · Cited by 8
Self-citationSchade, D., Drowley, L., Wang, Q., Plowright, A. T., & Greber, B. (2022) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2022.116782 · Cited by 8
Surviving Cancer without a Broken Heart
Caspi, O., & Aronson, D. (2019) · Rambam Maimonides Medical Journal · doi:10.5041/rmmj.10366 · Cited by 8
Cell sources and methods for producing organotypic in vitro human tissue models
Hayden, P. J. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-817202-5.00002-4 · Cited by 11
Advancing Cardiac Organoid Engineering Through Application of Biophysical Forces
Blazeski, A., García‐Cardeña, G., & Kamm, R. D. (2024) · IEEE Reviews in Biomedical Engineering · doi:10.1109/rbme.2024.3514378 · Cited by 8
Combinatorial approaches for novel cardiovascular drug discovery: a review of the literature
Brogi, S., Tabanelli, R., & Calderone, V. (2022) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2022.2104247 · Cited by 7
Keung, W., & Cheung, Y. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.650039 · Cited by 7
“In addition to AIC, 2D cultured hiPSC-CMs have also been shown to successfully demonstrate the cardiotoxic effects of TKIs in a high throughput manner (Sharma et al., 2017).”
BackgroundMethodGong, Y., Li, Y., Tang, J., Zheng, J., Witman, N., Jakob, P., Tan, Y., Liu, M., Chen, Y., Wang, H., et al. (2021) · Cardiovascular Toxicology · doi:10.1007/s12012-021-09709-3 · Cited by 7
Yiangou, L., Blanch-Asensio, A., de Korte, T., Miller, D. C., van Meer, B. J., Mol, M. P. H., van den Brink, L., Brandão, K. O., Mummery, C. L., & Davis, R. P. (2022) · Stem Cells · doi:10.1093/stmcls/sxac029 · Cited by 8
Omics-Based Platform for Studying Chemical Toxicity Using Stem Cells
Yan, H., Zhao, J., Huang, R., Xia, M., & Wang, D. (2017) · Journal of Proteome Research · doi:10.1021/acs.jproteome.7b00693 · Cited by 7
Exaggerated Cardiotoxicity of Sunitinib in Stressed 3-Dimensional Heart Muscles
Eschenhagen, T. (2018) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2018.01.011 · Cited by 7
Thomas, D., Yang, P. C.-M., Wu, J. C., & Sayed, N. (2025) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2025.09.008 · Cited by 7
Self-citationDifferentiation of Pluripotent Stem Cells for Disease Modeling: Learning from Heart Development
Chi, C., Roland, T. J., & Song, K. (2024) · Pharmaceuticals · doi:10.3390/ph17030337 · Cited by 7
“Sharma et al., through a high-throughput screening, identified that vascular endothelial growth factor receptor 2 (VEGFR2)/platelet-derived growth factor receptor (PDGFR)-inhibiting tyrosine kinase inhibitors caused cardiotoxicity in hiPSC-ECs [180].”
BackgroundMerits of hiPSC-Derived Cardiomyocytes for In Vitro Research and Testing Drug Toxicity
Wang, P.-H., Fang, Y., Liu, Y.-W., & Yeh, M.-L. (2022) · Biomedicines · doi:10.3390/biomedicines10112764 · Cited by 7
“hiPSC-CMs were subjected to a well-established Wnt signaling modulation protocol using a directed differentiation method [22,23].”
MethodEvaluating the efficacy and cardiotoxicity of EGFR-TKI AC0010 with a novel multifunctional biosensor
Jiang, D., Wei, X., Zhu, Y., Qiu, Y. L., Liu, X., Kong, L., Li, F., Liu, J., Zhuang, L., Wan, H., et al. (2023) · Microsystems & Nanoengineering · doi:10.1038/s41378-023-00493-4 · Cited by 6
Aghel, N., Gustafson, D., Delgado, D., Atenafu, E. G., Fish, J. E., & Lipton, J. H. (2023) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2023.2242990 · Cited by 6
“These observations are in line with clinical and in vitro studies examining nilotinib and ponatinib, which have highlighted pro-thrombotic angiopathies, decreased endothelial proliferation, and enhanced leukocyte adhesion [32,46–48].”
ResultChandy, M., Hill, T., Jiménez-Téllez, N., Wu, J. C., Sarles, S. E., Hensel, E. C., Wang, Q., Rahman, I., & Conklin, D. J. (2024) · Cardiovascular Toxicology · doi:10.1007/s12012-024-09850-9 · Cited by 7
“Cultures of iPSC-CMs could also be used for toxicity studies in tandem with atomic force microscopy, calcium imaging, patch clamping [66], and multielectrode array (MEA) [67, 68].”
Self-citationWu, W., Sun, J., Zhang, J., Zhao, H., Qiu, S., Li, C., Shi, C., & Xu, Y. (2024) · Toxicology · doi:10.1016/j.tox.2024.153830 · Cited by 6
In Vitro Toxicology: Next Generation Models and Methods to Improve Safety Evaluation
Fortin, M. C., & Szilagyi, J. T. (2024) · Springer eBooks · doi:10.1007/978-3-031-35529-5_120 · Cited by 8
Pang, L., Cai, C., Aggarwal, P., Wang, D., Vijay, V., Bagam, P., Blamer, J., Matter, A. M., Turner, A., Ren, L., et al. (2024) · Toxicological Sciences · doi:10.1093/toxsci/kfae041 · Cited by 9
Moon, S., Bae, D., Jung, T., Chung, E.-B., Jeong, Y.-H., Park, S., & Chung, H. (2017) · International Journal of Stem Cells · doi:10.15283/ijsc17024 · Cited by 7
Proteomic cellular signatures of kinase inhibitor-induced cardiotoxicity
Xiong, Y., Liu, T., Chen, T., Hansen, J., Hu, B., Chen, Y., Jayaraman, G., Schürer, S. C., Vidović, D., Goldfarb, J., et al. (2022) · Scientific Data · doi:10.1038/s41597-021-01114-3 · Cited by 6
“This strategy, which focuses on samples, instrument and analytical pipeline, has enabled us to ensure high quality at (1) the protein sample level, (2) the LC-MS/MS instrument performance level, and (3) the overall quantitative data processing variations.”
Yun, J., So, J., Jeong, S., Jang, J., Han, S., Jeon, J., Lee, K., Jang, H. R., & Lee, J. (2024) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-024-05493-9 · Cited by 5
Pharmacogenomics meets precision cardio-oncology: is there synergistic potential?
Hockings, J. K., Lal, J. C., & Cheng, F. (2020) · Human Molecular Genetics · doi:10.1093/hmg/ddaa134 · Cited by 6
“Furthermore, thet investigators confirmed nilotinib and vandetanib indeed induced QT prolongation as seen by reduced calcium handling, beating rate and action potential tracing (87).”
BackgroundLal, J. C., & Cheng, F. (2023) · Computational methods in engineering & the sciences · doi:10.1007/978-3-031-20730-3_24 · Cited by 5
Revolutionising Cardio-Oncology Care with Precision Genomics
Chong, J. H., Chuah, C. T. H., & Lee, C. G. L. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26052052 · Cited by 6
“…cardiomyocytes have been instrumental in characterising cellular disease phenotypes [127], facilitating high-throughput drug discovery [128], and investigating cardiovascular metabolism [129], among many other functions [130], thus cementing their key role in contemporary…”
Human pluripotent stem cell–based cardiovascular disease modeling and drug discovery
Liu, G., Liu, Z., & Cao, N. (2021) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-021-02542-1 · Cited by 5
“[77] carry out a screen for cardiovascular toxicity of TKIs using the iPSC platform, and their results correlate”
Heliste, J., Jokilammi, A., Vaparanta, K. M., Paatero, I., & Elenius, K. (2021) · Scientific Reports · doi:10.1038/s41598-021-96033-z · Cited by 5
Cardiovascular Toxicity in Cancer Therapy: Protecting the Heart while Combating Cancer
Manhas, A., Tripathi, D., Thomas, D., & Sayed, N. (2024) · Current Cardiology Reports · doi:10.1007/s11886-024-02099-2 · Cited by 6
“For example, research has demonstrated that sunitinib reduces the contractility of hiPSC-CMs in a concentration-dependent manner [30, 76].”
Self-citationCherubin, M., Delaunois, A. G., Valentin, J., Alaerts, M., Guns, P., & Gryshkova, V. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1584734 · Cited by 4
Feng, M.-Y., Tang, Y.-S., Yao, S., Zhang, H.-J., Bi-lin, L., Huang, R.-R., Huang, S., Ouyang, Z., Yuan, M., Jiang, R. S., et al. (2026) · Acta Pharmacologica Sinica · doi:10.1038/s41401-025-01704-6 · Cited by 5
Maas, R. G. C., Denning, C. N., & Sluijter, J. P. G. (2026) · Stem Cells Translational Medicine · doi:10.1093/stcltm/szag001 · Cited by 5
Woo, L. A., Wintruba, K. L., Wissmann, B., Tkachenko, S., Kubicka, E., Farber, E., Engkvist, O., Barrett, I. P., Granberg, K. L., Plowright, A. T., et al. (2024) · iScience · doi:10.1016/j.isci.2024.110485 · Cited by 4
Xian, H.-Q., Blanco, C., Bonham, K., & Snodgrass, H. R. (2022) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2022.115886 · Cited by 6
Mullen, M., Tan, W. L. W., Rhee, J., & Wu, J. C. (2022) · Heart Failure Clinics · doi:10.1016/j.hfc.2022.02.009 · Cited by 4
Self-citationKim, J., Kim, E., Lee, H., & Kim, K. (2023) · Animal Cells and Systems · doi:10.1080/19768354.2023.2189932 · Cited by 4
“Cardiomyocytes derived from human pluripotent stem cells are useful in vitro cardiac models for toxicity screening and drug evaluations (Liang et al. 2013; Wang et al. 2014; Sharma et al. 2017).”
BackgroundProgrammed spontaneously beating cardiomyocytes in regenerative cardiology
Inouye, K., Yeganyan, S., Kay, K., & Thankam, F. G. (2024) · Cytotherapy · doi:10.1016/j.jcyt.2024.03.004 · Cited by 4
Paying the Toll in Nuclear Reprogramming
Liu, C., Himmati, F., & Sayed, N. (2017) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2017.00070 · Cited by 4
“For example, lab-grown patientspecific tissues can be subjected to different treatments, like a virtual clinical trial without the need to administer a single drug to the patient (Matsa et al., 2016; Sharma et al., 2017).”
BackgroundSelf-citationQiao, Z., & Kondo, T. (2018) · Journal of Electrophoresis · doi:10.2198/jelectroph.62.17 · Cited by 4
Inselman, A. L., Liu, F., Wang, C., Shi, Q., Pang, L., Mattes, W. B., White, M. C., Lyn‐Cook, B. D., Rosas-Hernández, H., Cuevas, E., et al. (2019) · Toxicology in Vitro · doi:10.1016/j.tiv.2019.03.003 · Cited by 4
Pluripotent Stem Cell Modeling of Anticancer Therapy–Induced Cardiotoxicity
Lyra‐Leite, D. M., & Burridge, P. W. (2020) · Current Cardiology Reports · doi:10.1007/s11886-020-01325-x · Cited by 5
Self-citationZhang, Y. L., Chen, W., Pathak, A., Yang, Y., Yang, D., & Zhai, Y. (2022) · Journal of Comparative Effectiveness Research · doi:10.2217/cer-2022-0032 · Cited by 4
Self-citation
Metadata
- Authors
- Sharma, A., Burridge, P. W., McKeithan, W. L., Serrano, R., Shukla, P., Sayed, N., Churko, J. M., Kitani, T., Wu, H., Holmström, A., Matsa, E., Zhang, Y., Kumar, A., Fan, A. C., del Álamo, J. C., Wu, S. M., Moslehi, J. J., Mercola, M., & Wu, J. C.
- Affiliations
- Stanford Medicine (US)
- Northwestern University (US)
- Sanford Burnham Prebys Medical Discovery Institute (US)
- University of California San Diego (US)
- Department of Mechanical and Aerospace Engineering, University of California, San Diego, La Jolla, CA 92092, USA.
- Vanderbilt-Ingram Cancer Center (US)
- Corresponding author
- Sharma, Arun
- Burridge, Paul W.
- Wu, Joseph C.
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2017-02-15
- Volume
- 9
- Issue
- 377
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- PMC
- PMC5409837
- OpenAlex
- W2587938050
- Cited by
- 404
- References
- 49
- Citations by year
- 2026: 16 · 2025: 29 · 2024: 55 · 2023: 34 · 2022: 41 · 2021: 50 · 2020: 56 · 2019: 52 · 2018: 47 · 2017: 23
- FWCI
- 37.62
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institutes of Health (award280979)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Chemotherapy-induced cardiotoxicity and mitigation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac electrophysiology and arrhythmias
- Keywords
- tyrosine kinase inhibitors, cardiotoxicity, human induced pluripotent stem cell-derived cardiomyocytes, high-throughput screening, VEGFR-2 inhibitors, PDGFR inhibitors, endothelial cells, cardiac fibroblasts, insulin signaling, IGF-1 signaling, cardioprotection
- MeSH terms
- Fibroblasts, Humans, Insulin, Insulin-Like Growth Factor I, Models, Biological, Phosphorylation, Sarcomeres, Signal Transduction, Biomarkers, Myocytes, Cardiac, Vascular Endothelial Growth Factor Receptor-2, Protein Kinase Inhibitors, Induced Pluripotent Stem Cells, High-Throughput Screening Assays, Cardiotoxicity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.